Riskpilot← Back to searchSign inGet full accessIGM Biosciences A/S
A/SIn liquidationCVR 39123649Haldor Topsøes Allé 1Forskning og eksperimentel udvikling indenfor bioteknologi · NACE 721100Est. 2017— employees
Revenue 2017
—
EBITDA margin
—
Equity ratio
7.4%
Financial strength
Net profit 2017
DKK -580K
| Revenue | — | — |
| EBITDA | DKK -577K | — |
| Net profit | DKK -580K | — |
| Total assets | DKK 268,8M | — |
| Equity | DKK 19,9M | — |
| Employees | — | — |
Legal name
IGM Biosciences A/S
CVR number
39123649
Legal form
Aktieselskab
NACE code
721100 · Forskning og eksperimentel udvikling indenfor bioteknologi
Founded
29. november 2017
Share capital
DKK 707.710
Employees
—
VAT registered
No
Audit selected
No
Last report
2017-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af en likvidator
Address
Haldor Topsøes Allé 1
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2017 |
|---|---|
| Revenue | — |
| Staff expenses | -0 |
| EBITDA | -577 |
| Depreciation & amort. | -0 |
| EBIT | -577 |
| Net financials | -92 |
| Profit before tax | -669 |
| Tax | -89 |
| Net profit | -580 |
| Item | 2017 |
|---|---|
| Total assets | 268.788 |
| Equity | 19.884 |
| Long-term debt | 214.958 |
| Short-term debt | 33.946 |
| Total debt | 248.904 |
EBITDA margin
-57700000.0%
This company
15.8%
Market median
-365189973% vs market
20172017
Equity ratio
7.4%
This company
38.2%
Market median
-81% vs market
20172017
Return on equity
-2.9%
This company
18.4%
Market median
-116% vs market
20172017
Net profit margin
-58000000.0%
This company
8.1%
Market median
-716049483% vs market
20172017
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20172017
Debt / equity
12.52×
This company
0.62×
Market median
-1919% vs market
20172017
- Annual report 2017Filed via CVR / Virk · Period 2017-11-29 – 2017-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
MN Unofficial title | Unofficial title | 2018 | — | — |
HK Management | Management | 2017 | — | — |
FM Chief Executive Officer | Chief Executive Officer | 2017 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2017 | — | — | |
| Board of Directors | 2017 | — | — | |
| Chairman | 2018 | — | — | |
| Chairman | 2017 | — | — | |
| Board of Directors | 2018 | — | — | |
| Board of Directors | 2018 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Topsøe Holding A/S | Company | 66.7% | 66.7% | 2017 |
IGM Biosciences A/S | Company | 10.0% | 0.0% | 2017 |
| Individual | 5.0% | 5.0% | 2017 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of IGM Biosciences A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Michael Nørremark | Unofficial title | 0 companies |
| Hans Kornerup | Management | 0 companies |
| Fred Max Schwarzer | Chief Executive Officer | 0 companies |
| Christina Teng Topsøe | Board of Directors | 0 companies |
| Henrik Topsøe | Board of Directors | 0 companies |
| Michael Dewey Loberg | Chairman | 0 companies |
| Jakob Haldor Topsøe | Chairman | 0 companies |
| Dana Roy Leach | Board of Directors | 0 companies |
| Nelson Nan-Hsiong Teng | Board of Directors | 0 companies |